Kurse werden geladen...
Prognose
Kaufen |
0 |
Halten |
0
|
Verkaufen |
1 |
Scoring-Modelle
Dividenden-Strategie | 0 / 15 |
HGI-Strategie | 5 / 18 |
Levermann-Strategie | -4 / 13 |
Beliebteste Broker
News
- 18.09. - 16:00 Uhr
Aizon Launches New AI-powered eBR Light Solution to Enhance Manufacturing Productivity in Collaboration with Euroapi
SAN FRANCISCO--(BUSINESS WIRE)-- #gxp--Aizon, an Artificial Intelligence (AI) SaaS provider dedicated to transforming pharmaceutical manufacturing operations, is launching a new product called Aizon Execute, an innovative eBR (Electronic Batch Record) software product, developed in collaboration with Euroapi, a leading global API manufacturer. This collaboration was born out of the need to digitize operations towards more data-driven manufacturing - focusing on the essential user needs while avoiding. » Mehr auf businesswire.com
- 05.08. - 06:00 Uhr
EUROAPI - Availability of 2024 Half-Year Financial Report
Paris, 05 August, 2024 – EUROAPI posted today its 2024 condensed Half-Year Consolidated Financial Statements for the six months ended June 30, 2024. This document is available for consultation and downloading on EUROAPI's website: https://www.euroapi.com/en/investors/regulatory-information/financial-reports. » Mehr auf globenewswire.com
- 26.06. - 15:40 Uhr
EUROAPI is moving ahead with its FOCUS-27 plan, setting the foundations for future profitable growth1
Press Release Agreement with Sanofi on a 200 M€ investment through a Perpetual Subordinated Hybrid Bond, upon the completion of the ongoing discussions to amend and extend the current Revolving Credit Facility 75 to 80 M€ annual run-rate incremental Core EBITDA targeted by the end of 2027, driven by the end of higher value API and CDMO offering, a streamlined industrial footprint, and significant cost reductions Brindisi site expected to progressively resume shipments and production during Q3 2024 “FOCUS-27 is leading EUROAPI to a more agile, value-added, and rightsized business model. It will significantly improve the company's competitiveness and set the stage for long-term sustainable, profitable growth,” says Ludwig de Mot, Chief Executive Officer. » Mehr auf globenewswire.com
Unternehmenszahlen
(EUR) | Juni 2024 | |
---|---|---|
Umsatz | 225,45 Mio | 54,60% |
Bruttoeinkommen | 49,00 Mio | 48,04% |
Nettoeinkommen | 17,40 Mio | 127,71% |
EBITDA | 26,05 Mio | 53,73% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 342,48 Mio € |
Anzahl Aktien | 95,26 Mio |
52 Wochen-Hoch/Tief | 11,56 € - 2,50 € |
Dividenden | Nein |
Beta | 0,56 |
KGV (PE Ratio) | 0,82 |
KGWV (PEG Ratio) | 0,00 |
KBV (PB Ratio) | 0,38 |
KUV (PS Ratio) | 0,28 |
Unternehmensprofil
Euroapi SA entwickelt, produziert, vermarktet und vertreibt pharmazeutische Wirkstoffe und Zwischenprodukte für die Formulierung von Human- und Tierarzneimitteln. Das Unternehmen wurde im Jahr 2021 gegründet und hat seinen Sitz in Paris, Frankreich.
Name | EUROAPI |
CEO | Ludwig De Mot |
Sitz | Paris,
Frankreich |
Website | |
Börsengang | 06.05.2022 |
Mitarbeiter | 3.650 |
Ticker Symbole
Börse | Symbol |
---|---|
Euronext | EAPI.PA |
Pnk | EAPIF |
Frankfurt | 940.F |
Düsseldorf | 940.DU |
London | 0EAP.L |
Paris | EAPI.PA |
München | 940.MU |
Assets entdecken
Shareholder von EUROAPI investieren auch in folgende Assets